5R01AG061122-04 |
2022 |
$1520269 |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |
3R01AG061122-03S1 |
2022 |
$5526538 |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |
5R01AG061122-03 |
2021 |
$5526539 |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |
5R01AG061122-02 |
2020 |
$3102477 |
Phase 2 Randomized; Double-Blind; Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |
3R01AG061122-02S1 |
2020 |
$2396962 |
Phase 2 Randomized; Double-Blind; Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |
1R01AG061122-01 |
2019 |
$2292799 |
Phase 2 Randomized; Double-Blind; Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects |